These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31008763)

  • 1. Immune Checkpoint Inhibitors-Related Cardiotoxicity.
    Konala VM; Adapa S; Aronow WS
    Am J Ther; 2020; 27(6):e591-e598. PubMed ID: 31008763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical predictive value of PD-1/PD-L1-induced electrocardiogram changes for cardiotoxicity].
    Xue N; Peng LL; Wu DW; Li XJ
    Zhonghua Zhong Liu Za Zhi; 2024 Oct; 46(10):979-986. PubMed ID: 39414599
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
    Pirozzi F; Poto R; Aran L; Cuomo A; Galdiero MR; Spadaro G; Abete P; Bonaduce D; Marone G; Tocchetti CG; Varricchi G; Mercurio V
    Curr Oncol Rep; 2021 Jan; 23(2):13. PubMed ID: 33415405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
    Hajem S; Ederhy S; Champiat S; Troalen F; Nolin-Lapalme A; Berhoune M; Cauquil C; Martin-Romano P; Baldini C; Laparra A; Vuagnat P; Hollebecque A; Mateus C; Besse B; Naltet C; Robert C; Marabelle A; Massard C; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 157():383-390. PubMed ID: 34571335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
    Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
    Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
    Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
    Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
    Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
    Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
    Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
    Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
    Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
    Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
    Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity of immune checkpoint inhibitors.
    Varricchi G; Galdiero MR; Marone G; Criscuolo G; Triassi M; Bonaduce D; Marone G; Tocchetti CG
    ESMO Open; 2017; 2(4):e000247. PubMed ID: 29104763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
    Ghosh N; Tirpack A; Chan KK; Bass AR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.